A Phase II/III trial of CAN008 as second-line treatment of GBM in Mainland China

Trial Profile

A Phase II/III trial of CAN008 as second-line treatment of GBM in Mainland China

Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Asunercept (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2018 New trial record
    • 12 Apr 2018 According to a CANbridge Life Sciences media release, company anticipates dosing the first patient later this year
    • 12 Apr 2018 According to a CANbridge Life Sciences media release, the China Food and Drug Administration (CFDA) has approved the Investigational New Drug (IND) application for a Phase II/III clinical study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top